The Neighborhoods Study: Contextual Disadvantage and Alzheimer’s Disease and Related Dementias (ADRD)
The Neighborhoods Study: Contextual Disadvantage and Alzheimer’s Disease and Related Dementias (ADRD)
批准号:
10803585
负责人:
Barbara Brigitta Bendlin
金额:
$349.4万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-03-01 至 2026-02-28
关键词:
AddressAgeAlzheimer&aposs DiseaseAlzheimer&aposs disease related dementiaAmyloidAnimal ModelAreaAtlasesAutopsyBackBehaviorBiologicalBiological ProcessBiological Specimen BanksBrainCaliforniaClinicalCodeCognitiveCollaborationsConsentDataDementiaDevelopmentDiagnosisDisadvantagedDiseaseDisparityDistalDoseEducationEmploymentEthnic OriginEvaluationExposure toFoundationsFundingFutureGeographyGoalsHealthHealth behaviorHousingHumanImpaired cognitionIncomeIndividualIndividual AdjustmentIndustryInfrastructureInterdisciplinary StudyLife Cycle StagesLinkMagnetic Resonance ImagingMediatingMediatorMethodologyMissionNational Institute on AgingNeighborhoodsNerve DegenerationOutcomeParticipantPartner in relationshipPathologicPathway interactionsPersonsPhenotypePopulations at RiskPositron-Emission TomographyPovertyPrevalenceRaceRecording of previous eventsResearchResearch DesignResearch SupportRiskRisk AssessmentRisk FactorsSamplingScienceStandardizationSurveysTimeTissuesUniversitiesWisconsinWorkburden of illnesscognitive changecognitive functioncomorbiditydeprivationdosageeffective interventionethnic minorityimprovedindexingmortalityneighborhood associationneighborhood disadvantageneuroimagingneuropathologyneurophysiologynovelnovel therapeutic interventionnovel therapeuticsprospectivepublic databaseracial minorityrandomized trialsecondary outcomesexsocialsocial health determinantssocioeconomic disadvantagesocioeconomicssociologisttau Proteinstheoriestherapy development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Dementia due to Alzheimer’s disease and related dementias (ADRD) disproportionately impacts racial/ethnic
minorities and the socioeconomically disadvantaged. Development of effective interventions require mechanistic
understanding of distal fundamental forces, including socioeconomic context (i.e. “neighborhood disadvantage”
or the social determinants of health of a given area), that put people at “risk for [more proximal] risks” such as
individual-level income, education, health behaviors and comorbidity. Prior research supports that contextual
disadvantage is modifiable and interacts with biological processes to produce disease, yet little is known of its
impact on ADRD. Towards this, we created validated quantifications of neighborhood disadvantage for the full
US. This Area Deprivation Index (ADI) incorporates poverty, education, housing and employment indicators;
predicts disparity-related health outcomes; and is freely shared through our public platform (the Neighborhood
Atlas). We have validated survey and public data-based residential history tracing methodologies that establish
dosage and timing of neighborhood disadvantage exposure across a life-course for both living and deceased
persons. We have demonstrated that even after adjustment for individual risk factors, neighborhood
disadvantage is strongly associated with cognitive function, neurodegeneration shown on MRI, and post-mortem
AD plaque neuropathology. However, our current sample is lacking in geographic diversity and is of insufficient
size to conduct a more robust multi-factor phenotypic risk assessment of social-biological interactions and their
mechanisms; a necessary foundation towards developing new therapeutic intervention. This proposal employs
collaboration with 22 Alzheimer’s Disease Research Centers (ADRC) and their existing cognitive, neuroimaging
and neuropathology data. We take on the substantial work to create detailed residential histories for each ADRC
subject (N~9,234 living, N~10,469 brain bank) to establish a dosage and timing of neighborhood disadvantage
exposure across each life-course. Hypothesis: Larger and earlier exposures to neighborhood disadvantage will
predict lower cognitive function, faster cognitive decline and greater disease burden including AD neuropathology
among the targeted sample. Aim 1: Determine the impact of the cumulative dose and timing of neighborhood
disadvantage exposure (indexed by ADI), on cognitive function and change over time; Aim 2: on AD-specific
markers indexed by neuroimaging (amyloid and tau PET) and the secondary outcome of volumetric MRI; and
Aim 3: on neuropathologic tissue features and diagnosis. Aim 4: Using existing ADRC data and newly collected
survey data, define the extent to which individual race/ethnicity, age, sex, income, education, comorbidity and
health-behaviors mediate these relationships. The proposed project, if funded, will be the largest study of its kind
on social determinants of health in the context of AD. Successful completion will result in the development of a
novel collaborative infrastructure of contextual exposure for future social-biological phenotypic evaluation,
providing a potential pathway to new therapeutics, and directly responsive to the NIA mission.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ß-hydroxybutyrate inhibition of pathology in Alzheimer's disease
-
批准号:10739679
-
项目类别:
-
资助金额:$75.24万
-
财政年份:2023
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
Administrative Supplement to Establish National Exposome Alzheimer's Disease and Related Dementias (ADRD) Infrastructure (Expo-AD)
-
批准号:10658250
-
项目类别:
-
资助金额:$345.15万
-
财政年份:2021
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
Gut barrier function in Alzheimer’s disease
-
批准号:10614373
-
项目类别:
-
资助金额:$73.99万
-
财政年份:2021
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
The Neighborhoods Study: Contextual Disadvantage and Alzheimer’s Disease and Related Dementias (ADRD)
-
批准号:10361428
-
项目类别:
-
资助金额:$630.81万
-
财政年份:2021
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
Gut barrier function in Alzheimer’s disease
-
批准号:10350685
-
项目类别:
-
资助金额:$74.82万
-
财政年份:2021
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
The Neighborhoods Study: Contextual Disadvantage and Alzheimer’s Disease and Related Dementias (ADRD)
-
批准号:10580795
-
项目类别:
-
资助金额:$635.49万
-
财政年份:2021
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
Research Education Component
-
批准号:10385840
-
项目类别:
-
资助金额:$22.26万
-
财政年份:2019
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
Research Education Component
-
批准号:10601075
-
项目类别:
-
资助金额:$21.5万
-
财政年份:2019
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
SV2A PET imaging in Alzheimer's Disease
-
批准号:9919489
-
项目类别:
-
资助金额:$113.34万
-
财政年份:2018
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
SV2A PET imaging in Alzheimer's Disease
-
批准号:10403978
-
项目类别:
-
资助金额:$112.92万
-
财政年份:2018
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
SV2A PET imaging in Alzheimer's Disease
-
批准号:10177835
-
项目类别:
-
资助金额:$113.14万
-
财政年份:2018
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
Diet and Exercise Trial to Improve Insulin Resistance, Increase Cerebral Blood Flow, Alter Metabolomic Biomarkers, and Decrease Alzheimer's Disease Risk
-
批准号:9166391
-
项目类别:
-
资助金额:$22.95万
-
财政年份:2016
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
White matter degeneration: biomarkers in preclinical Alzheimer's Disease
-
批准号:10606478
-
项目类别:
-
资助金额:$75.62万
-
财政年份:2012
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
White matter degeneration: biomarkers in preclinical Alzheimer's Disease
-
批准号:10390318
-
项目类别:
-
资助金额:$76.01万
-
财政年份:2012
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
White matter degeneration: biomarkers in preclinical Alzheimer's Disease
-
批准号:8461579
-
项目类别:
-
资助金额:$29.16万
-
财政年份:2012
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
White matter degeneration: biomarkers in preclinical Alzheimer's Disease
-
批准号:8667387
-
项目类别:
-
资助金额:$30.52万
-
财政年份:2012
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
White matter degeneration: biomarkers in preclinical Alzheimer's Disease
-
批准号:8297257
-
项目类别:
-
资助金额:$30.85万
-
财政年份:2012
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
Midlife Insulin Resistance and Obesity: Risk Factors for AD-Related Brain Change
-
批准号:8829118
-
项目类别:
-
资助金额:$12.94万
-
财政年份:--
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
Midlife Insulin Resistance and Obesity: Risk Factors for AD-Related Brain Change
-
批准号:8677363
-
项目类别:
-
资助金额:$13.34万
-
财政年份:--
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
Midlife Insulin Resistance and Obesity: Risk Factors for AD-Related Brain Change
-
批准号:9261450
-
项目类别:
-
资助金额:$13.34万
-
财政年份:--
-
负责人:Barbara Brigitta Bendlin
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: